Skip to main content
Premium Trial:

Request an Annual Quote

Even as Economy Slows, RNAi, miRNA Players Find Interested Partners in 2008

Premium
Despite the difficult economic climate, a number of RNAi and microRNA drug developers were able to secure important alliances, or even buyouts, with big pharmaceutical and biotechnology firms over the course of 2008.
 
“People continue to have strong interest in RNA as a therapeutic,” Lou Renzetti, vice president and global head of RNA therapeutics at Roche, told RNAi News earlier this month. “Those of us who have managed to make strategic investments and can ride [the financial upheaval] out … remain committed.”
 
To view a snapshot of key RNAi/miRNA partnerships forged over the past 12 months, click here.